UNITED THERAPEUTICS Corp Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
UNITED THERAPEUTICS Corp quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2019 to Q3 2024.
  • UNITED THERAPEUTICS Corp Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $309M, a 15.5% increase year-over-year.
  • UNITED THERAPEUTICS Corp Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $1.11B, a 23.5% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Net Income (Loss) Attributable to Parent for 2023 was $985M, a 35.4% increase from 2022.
  • UNITED THERAPEUTICS Corp annual Net Income (Loss) Attributable to Parent for 2022 was $727M, a 52.9% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.11B $309M +$41.5M +15.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $1.07B $278M +$18.9M +7.29% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $1.05B $307M +$65.7M +27.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $985M $217M +$85M +64.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $900M $268M +$28.3M +11.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $872M $259M +$143M +123% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $728M $241M +$1M +0.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $727M $132M +$19.9M +17.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $707M $239M +$76.6M +47.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $631M $116M -$56.6M -32.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $687M $240M +$212M +748% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $476M $112M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $163M -$8.5M -4.97% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $173M +$65.5M +61.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $28.3M -$109M -79.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q3 2020 $171M +$38.8M +29.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $107M -$98M -47.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $138M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q3 2019 $132M Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $205M Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.